Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Lactobacillus composition for inhibiting gastritis caused by helicobacter pylori in stomach and application thereof

A technology of Helicobacter pylori and lactic acid bacteria, applied in the direction of Lactobacillus, drug combination, and microbial-based methods, can solve the problems of inability to eradicate Helicobacter pylori infection, Helicobacter pylori drug resistance, abnormal taste, etc.

Active Publication Date: 2019-12-31
景岳生物科技(中国)有限公司
View PDF7 Cites 7 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, Helicobacter pylori is prone to develop resistance to antibiotics, so two antibiotics plus bismuth salts or proton pump inhibitors are currently administered in combination in a three-in-one or four-in-one therapy; the main side effects of these drugs are abnormal taste, Nausea, diarrhea, flatulence, headache, dizziness and other obvious side effects, if the patient stops the drug on his own, it is more likely to lead to drug resistance of Helicobacter pylori
Generally speaking, about 10-20% of patients cannot eradicate Helicobacter pylori infection due to the above reasons. Therefore, there is still room for improvement in the existing treatment of Helicobacter pylori infection

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Lactobacillus composition for inhibiting gastritis caused by helicobacter pylori in stomach and application thereof
  • Lactobacillus composition for inhibiting gastritis caused by helicobacter pylori in stomach and application thereof
  • Lactobacillus composition for inhibiting gastritis caused by helicobacter pylori in stomach and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0026] Example 1. Screening of lactic acid bacteria that can be highly adsorbed to human gastric cells (AGS)

[0027] Human gastric epithelial cells AGS (ATCC CRL 1739) were co-cultured with activated lactic acid bacteria (bacterial infection dose MOI: 100) for 2 hours, then washed with PBS to remove unadsorbed bacteria, and stained with Giemsa stain. The number of lactic acid bacteria adsorbed on human gastric epithelial cells (AGS) was observed under a microscope to evaluate the strength of the adsorption of the strains.

[0028] figure 1 Observe under the visual field of the oil immersion lens, if more than 40 lactic acid bacteria strains are adsorbed on the cells (such as figure 1 shown in A), expressed by "++++", which means that the ability to bind to the cells is the strongest; more than 20 lactic acid bacteria strains are adsorbed on the cells (such as figure 1 shown in middle B), represented by "+++"; more than 10 lactic acid bacteria strains adsorbed on the cells (...

Embodiment 2

[0030] Example 2. Screening of lactic acid bacteria that can highly inhibit Helicobacter pylori-induced IL-8 secretion and NF-κB transcription factor-related inflammatory response

[0031] Gastric epithelial cells infected with Helicobacter pylori were co-cultured with different strains of lactic acid bacteria (13 strains selected in the previous step) for 16 hours, and then the expression of IL-8 was analyzed by ELISA method, and NF-κB-luciferase After the (NF-κB luciferase) construct was transfected into the gastric epithelial cells, and lactic acid bacteria and Helicobacter pylori were added to co-culture for 12 hours, the activity of the inflammatory response caused by Helicobacter pylori could be known by analyzing the activity of NF-κB-luciferase. And further analysis whether the lactic acid bacteria have inhibitory effect.

[0032] The analysis results are shown in Table 1. It can be seen from the table that Lactobacillus rhamnosus GM-020 (also known as GMNL-74, present...

Embodiment 4

[0044] Embodiment four, the composition of three strains of lactic acid bacteria has the effect of additively inhibiting antibiotic-sensitive HP or multidrug-resistant HP strains

[0045] The ability of lactic acid bacteria to resist Helicobacter pylori strains was analyzed by agar-well diffusion method and antibacterial test. The H.pylori pathogenic strains used include: H.pylori BCRC 26695 (ATCC700392): wild-type strain, sensitive to antibiotics metronidazole (metronidazole) and clarithromycin (clarithromycin); H.pylori v633: Resistance to the antibiotic metronidazole (MZ R ) and clarithromycin resistant (CH R ); H.pylori v2311: resistant to the antibiotic metronidazole (MZ R ), but sensitive to clarithromycin (CH S ). H.pylori were placed under microaerobic conditions (85% N 2 , 10% CO 2 , 5%O 2 ) and Brucella blood agar plate (BAP) culture medium, the pathogenic bacteria were scraped off and the concentration of pathogenic bacteria was adjusted to 1×10 with phosphat...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the field of health-care food, in particular to a lactobacillus composition for inhibiting gastritis caused by helicobacter pylori in stomach and an application of the lactobacillus composition. The invention provides a pharmaceutical composition for inhibiting gastritis caused by gastric helicobacter pylori and a food product. Wherein the lactobacillus is selected from lactobacillus rhamnosus GM-020 and also called as GMNL-74 with a preservation number of the lactobacillus rhamnosus GM-020 being CCTCC NO: M203098, the lactobacillus acidophilus GMNL-185 with the preservation number of CCTCC NO: M2017764, and lactobacillus plantarum GMNL-662 with the preservation number CCTCC NO: M2016571, and a group formed by combining any two or more of the above components.

Description

technical field [0001] The invention relates to the field of health food, in particular to the use of a lactic acid bacteria composition for preparing a composition for inhibiting gastric Helicobacter pylori-induced gastritis. Background technique [0002] Helicobacter pylori (H.pylori) is a microaerophilic Gram-negative bacterium that may cause: gastric ulcer, duodenal ulcer, chronic gastritis ), gastric mucosa-associated lymphoma (mucosa-associated lymphoid tissuelymphoma), and even gastric adenocarcinoma (gastric adenocarcinoma)... and other gastrointestinal-related diseases. Helicobacter pylori mainly uses its urease to decompose urea to produce ammonia and carbon dioxide (CO 2 ), ammonia reacts with water to produce basic ammonium ions (NH4 + ) to neutralize gastric acid and increase the pH value of the mucosa to pH 4.5-7.0, so that bacteria can survive in the gastric environment for a long time (Eaton KA, Suerbaum S, Josenhans C and Krakowka S.1996). In addition, He...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C12N1/20A61K35/747A61P1/04A23L33/135C12R1/23
CPCA61K35/747A61P1/04A23L33/135A23V2002/00C12R2001/23C12N1/205A23V2400/175A23V2400/113A23V2400/169A23V2200/3204A61K2300/00
Inventor 陈奕兴蔡宛桦陈雅惠赖志河林宥欣
Owner 景岳生物科技(中国)有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com